Repligen (RGEN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
Shareholders are asked to vote for the re-election of Dr. Martin D. Madaus, Glenn P. Muir, Karen A. Dawes, and Carrie Eglinton Manner at the 2026 Annual Meeting.
ISS and Glass Lewis recommended voting against certain directors due to material weaknesses in internal controls and incomplete diversity disclosures, but the Board disagrees and outlines remediation progress.
Two material weaknesses in internal controls have been fully remediated since 2023, with ongoing efforts to address remaining issues in IT general controls and business process controls.
Significant organizational investments and leadership hires have been made to strengthen the control environment and accelerate remediation.
EY has issued unqualified opinions on the company’s financial statements for 2024 and 2025.
Voting matters and shareholder proposals
Proposal 1 is the election of directors, with the Board recommending votes in favor of all nominees.
Proxy solicitor Okapi Partners has been engaged to assist in soliciting proxies for the meeting.
Board of directors and corporate governance
The Board emphasizes the qualifications and experience of the nominated directors, highlighting their diverse backgrounds and industry expertise.
The Nominating and Corporate Governance Committee is committed to board diversity, with approximately 44% of members diverse in gender and/or ethnicity.
Aggregate board-level gender and racial/ethnic demographic data is disclosed in the appendix.
Latest events from Repligen
- Double-digit growth in FY25 with strong FY26 outlook and margin expansion despite headwinds.RGEN
Q4 202510 Apr 2026 - Proxy covers director elections, auditor ratification, executive pay, and strong 2025 growth.RGEN
Proxy filing2 Apr 2026 - Key votes include board elections, auditor ratification, and executive pay approval.RGEN
Proxy filing2 Apr 2026 - Broad innovation, strong execution, and digital focus drive multi-year growth outlook.RGEN
2026 KeyBanc Capital Markets Healthcare Forum18 Mar 2026 - Bioprocessing leader targets $810M–$840M FY26 revenue and ~30% EBITDA margin by 2030.RGEN
Investor presentation10 Mar 2026 - 2026 outlook features robust growth, margin expansion, and strategic global investments.RGEN
Leerink Global Healthcare Conference 202610 Mar 2026 - Q2 revenue declined year-over-year, but order momentum and liquidity remain strong.RGEN
Q2 20242 Feb 2026 - Above-market growth driven by innovation, key accounts, and new modalities, with margin recovery ahead.RGEN
Jefferies Global Healthcare Conference1 Feb 2026 - Innovation, M&A, and advanced analytics drive growth amid protein headwinds and market recovery.RGEN
The 44th Annual William Blair Growth Stock Conference1 Feb 2026